Santhera Provides Update on Timeline for Application of Raxone® in Duchenne Muscular Dystrophy in Europe

Liestal, Switzerland, May 19, 2017 – Santhera Pharmaceuticals, a specialty pharmaceutical company focused on the development of innovative treatments for rare mitochondrial and neuromuscular diseases, announces an updated timeline for the ongoing assessment by the Committee for Medicinal Products for Human Use (CHMP) of its extension application for Raxone® (idebenone) in Duchenne muscular dystrophy (DMD).